NEW YORK (GenomeWeb News) – Diagnoplex and Debiopharm Diagnostics, part of the Debiopharm Group, today announced that Diagnoplex has secured CHF1.3 million ($1.4 million) in financing.
Debiopharm led the round, while Neomed and Capital Romandie also participated in the financing.
Diagnoplex will use the funds to support its efforts to obtain CE marking for Colox, a non-invasive, blood-based test for the early detection of colorectal cancer. The Lausanne, Switzerland-based firm also hopes to prepare a comparative clinical trial for Colox.
Colox is a PCR-based gene signature test comprised of 29 biomarkers, according to Diagnoplex's website.
In a statement, Diagnoplex Founder and CEO Stavros Therianos said the funding will enable the firm to continue its development and progress in "establishing a collaboration for the commercialization of its diagnostic test."
Debiopharm also invested in Diagnoplex in early 2011. In its initial Series A financing round the company raised about $10.4 million.